Fosun Pharma Sells 4.55% Gland Pharma Stake For Rs 2,121 Crore

Fosun Pharma Industrial Pte Ltd, a promoter of Gland Pharma, has sold 75.05 lakh shares of the company through block deals on the BSE, reducing its stake in the Hyderabad-based pharmaceutical company. The shares, which represented a 4.55% stake in Gland Pharma, were sold for Rs 2,121.50 crore.

The transactions were executed at an average price of Rs 2,826.60 per share. Following the sale, Fosun Pharma's holding in Gland Pharma dropped below the 50% mark to 47.22% from 51.77%. This marks the second major stake sale by Fosun Pharma in Gland Pharma in just over two years, with the first being a 6% stake sale for Rs 1,754 crore in June 2024.

Several domestic mutual funds, insurance companies, and foreign investors acquired shares through the transactions. Kotak Mahindra Mutual Fund was the biggest buyer, purchasing 27.93 lakh shares, representing nearly 1.7% stake, for Rs 789.47 crore. Other buyers included Axis Mutual Fund, ICICI Prudential Mutual Fund, Aditya Birla Sun Life Mutual Fund, and SBI Life Insurance.

Gland Pharma shares ended nearly 1% higher at Rs 2,932.40 on the BSE. The company reported a 47% rise in consolidated net profit to Rs 317 crore for the April-June quarter, with revenue increasing 19.5% to Rs 1,800 crore from Rs 1,506 crore a year earlier.

Fosun Pharma had acquired about 74% of Gland Pharma in October 2017 at a valuation of up to USD 1.09 billion. The recent stake sale is a significant development in the pharmaceutical industry, with Gland Pharma being a major player in the sector.

The sale of shares by Fosun Pharma is expected to have a significant impact on the company's ownership structure. With the stake sale, Fosun Pharma's holding in Gland Pharma has fallen below the 50% mark, which may lead to changes in the company's management and strategy.

Gland Pharma has been performing well in recent times, with the company receiving tentative approval for Angiotensin II Injection. The company's financial performance has also been strong, with a 47% rise in consolidated net profit in the April-June quarter.

In conclusion, the stake sale by Fosun Pharma in Gland Pharma is a significant development in the pharmaceutical industry. The sale of shares worth Rs 2,121.50 crore has reduced Fosun Pharma's holding in the company to 47.22%, which may lead to changes in the company's ownership structure and management. The development is expected to have a significant impact on the pharmaceutical industry, with Gland Pharma being a major player in the sector.

The recent stake sale is also expected to have a positive impact on the company's shares, with Gland Pharma shares ending nearly 1% higher at Rs 2,932.40 on the BSE. The company's strong financial performance and recent approvals are expected to drive growth in the company's shares in the coming times.

Overall, the stake sale by Fosun Pharma in Gland Pharma is a significant development in the pharmaceutical industry, with the company's ownership structure and management expected to undergo changes in the coming times. The development is expected to have a significant impact on the company's shares and the pharmaceutical industry as a whole.

In terms of significance for Mumbai, the stake sale by Fosun Pharma in Gland Pharma is a major development in the pharmaceutical industry, which has a significant presence in the city. The development is expected to have a positive impact on the city's economy, with the pharmaceutical industry being a major contributor to the city's GDP.

The stake sale is also expected to attract more investment to the city, with the pharmaceutical industry being a major attraction for investors. The development is expected to create new job opportunities and drive growth in the city's economy.

In conclusion, the stake sale by Fosun Pharma in Gland Pharma is a significant development in the pharmaceutical industry, with the company's ownership structure and management expected to undergo changes in the coming times. The development is expected to have a significant impact on the company's shares and the pharmaceutical industry as a whole, and is also expected to have a positive impact on Mumbai's economy.